HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.
AIDS Behav. 2012 Oct;16(7):1761-74. doi: 10.1007/s10461-011-0028-6.
This study assessed acceptability of the candidate microbicide VivaGel(®) and two placebo gels among 61 sexually active young US and Puerto Rican women at three sites. Participants were randomly assigned to use one of the gels twice per day for 14 days. At trial completion, 59% of the women in the VivaGel(®) group reported being likely to use the gel in the future, whereas 23% were unlikely to use it and 18% were undecided. Participants reported problems with all three gels, including the "universal" placebo containing hydroxyethyl cellulose (HEC). The most frequent complaints were leakage, interference with sexual behavior, and decreased sexual satisfaction. Some of the complaints are not new but remain unresolved. Women's perceived risk of HIV infection may determine whether the gels are used. Users also may want a choice of viscosity. Poor acceptability of vaginal microbicide formulations may result in poor adherence to gel use during efficacy trials and compromise validity of results.
本研究评估了候选杀微生物剂 VivaGel(®)和两种安慰剂凝胶在三个地点的 61 名活跃的美国和波多黎各年轻女性中的可接受性。参与者被随机分配每天使用其中一种凝胶两次,持续 14 天。在试验结束时,VivaGel(®)组中有 59%的女性表示将来可能会使用该凝胶,而 23%的女性表示不太可能使用,18%的女性表示不确定。参与者报告了所有三种凝胶的问题,包括含有羟乙基纤维素 (HEC)的“通用”安慰剂。最常见的抱怨是泄漏、性行为干扰和性满意度下降。其中一些抱怨并不是新的,但仍未得到解决。女性对 HIV 感染的感知风险可能决定她们是否使用这些凝胶。使用者可能还希望选择不同的黏度。阴道杀微生物剂配方的可接受性差可能导致在疗效试验中对凝胶使用的依从性差,并影响结果的有效性。